Last reviewed · How we verify
Aralasin (SARALASIN)
Aralasin works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure.
Aralasin (SARALASIN) is a small molecule drug developed by Procter and Gamble that targets the type-2 angiotensin II receptor. It is classified as a saralasin and works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure. However, it is not FDA-approved for any indications and is currently off-patent. As a result, there are no generic manufacturers of Aralasin. Its commercial status and safety considerations are limited due to its off-patent status.
At a glance
| Generic name | SARALASIN |
|---|---|
| Sponsor | Procter And Gamble |
| Drug class | saralasin |
| Target | Type-2 angiotensin II receptor, Type-1 angiotensin II receptor, Angiotensin II receptor (AT-1) type-1 |
| Modality | Recombinant protein |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1982 |
Mechanism of action
Think of angiotensin II like a key that unlocks blood vessels, making them narrower and increasing blood pressure. Aralasin is like a lock that blocks this key, preventing blood vessels from constricting and reducing blood pressure. This can help people with high blood pressure by making it easier for blood to flow through their blood vessels.
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |